In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?
Boehringer gets diggi with it.